drugset / Trial / NCT02603575
Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients
RandomizedCrossoverOpen-labelTreatment
Summary
Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.
Timeline
- Start
- 2015-11
- Primary completion
- 2020-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caspofungin | Other / unclassified | 50 mg | Intravenous |
| Subject | Prednisone | Other / unclassified | 20 mg | Intravenous |